CHCWM – Cancer & Hematology Centers of West Michigan

INBRX-105 (InhibRx)

Description:  An Open Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-105 in Subjects with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma

Mechanism of Action:  IgG1 antibody that targets PD-L1 and costimulatory receptor 4-1BB

 

Target Patient Population:  PD-L1+ (CPS ≥ 5) Melanoma, NSCLC, Head and Neck Squamous cell

Study Design:  Drug is given IV every 3 weeks